Replay: Unleashing The Power Of PROs Throughout Oncology Drug Development
Source: Signant Health
Given the recent draft guidance from the FDA regarding core patient-reported outcomes (PROs) in cancer trials and dose optimization in oncology drug development, the careful gathering and analysis of patient experience data in oncology clinical research are increasingly vital.
Our top eCOA science and oncology research specialists have delved into various scenarios and provided actionable advice for enhancing PRO measurement strategies in oncology drug development, spanning from initial phases to phase III trials.
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
Signant Health
This website uses cookies to ensure you get the best experience on our website. Learn more